ResearchMoz added Latest Research Report titled " Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics " to it's Large Report database.
In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.
The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=716914
There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.
Scope
Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021
What is the generic penetration?
Which drugs will achieve blockbuster status?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Etiology 11
2.3.2 Pathophysiology 12
2.3.3 Tumor Initiation 13
2.3.4 Enhanced Growth, Evasion of Apoptosis and Replicative Immortality 14
2.3.5 Tumor Metabolic Shift 17
2.3.6 Tumor Progression, Invasion and Metastasis 17
2.3.7 Evasion of the Immune Response 19
2.3.8 Cancer Stem Cells 20
2.4 Co-morbidities and Complications 20
2.5 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 21
2.5.1 Breast Cancer 22
2.5.2 Colorectal Cancer 22
2.5.3 Lung Cancer 23
2.5.4 Prostate Cancer 24
2.6 Treatment 25
2.6.1 Surgery and Radiation Therapy 26
2.6.2 Chemotherapy 27
2.6.3 Hormonal Therapies 29
2.6.4 Targeted Therapies 30
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.
The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=716914
There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.
Scope
Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021
What is the generic penetration?
Which drugs will achieve blockbuster status?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Etiology 11
2.3.2 Pathophysiology 12
2.3.3 Tumor Initiation 13
2.3.4 Enhanced Growth, Evasion of Apoptosis and Replicative Immortality 14
2.3.5 Tumor Metabolic Shift 17
2.3.6 Tumor Progression, Invasion and Metastasis 17
2.3.7 Evasion of the Immune Response 19
2.3.8 Cancer Stem Cells 20
2.4 Co-morbidities and Complications 20
2.5 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 21
2.5.1 Breast Cancer 22
2.5.2 Colorectal Cancer 22
2.5.3 Lung Cancer 23
2.5.4 Prostate Cancer 24
2.6 Treatment 25
2.6.1 Surgery and Radiation Therapy 26
2.6.2 Chemotherapy 27
2.6.3 Hormonal Therapies 29
2.6.4 Targeted Therapies 30
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment